Camel-IDS NV-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Camel-IDS NV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014142
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Camel-IDS NV (Camel-IDS) is a biotechnology company which develops targeted radionuclide therapeutic solutions for the treatment of cancer. The company focuses on developing its lead compound radiopharmaceutical drug for treatment of Her2 positive cancer. Its technology platform is based on recombinant, small antigen-binding fragments derived from Camelidae heavy-chain-only antibodies (sdAbs) coupled with radioisotope to kill cancer cells. The company works in partnership with research institutions and organizations such as Vrije Universiteit Brussel (VUB), UZ Brussel, Fournier-Majoie Foundation, Biowin and VIB (Life Sciences Research Institute). Camel-IDS is headquartered in Brussels, Belgium.

Camel-IDS NV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Camel-IDS NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Camel-IDS NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Camel-IDS NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Camel-IDS NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Camel-IDS NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Camel-IDS NV, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Camel-IDS Raises USD1.5 Million in Seed Financing 10
Camel-IDS Plans to Raise USD7 Million in Series A Financing 11
Licensing Agreements 12
Camel-IDS Enters into Licensing Agreement with Vrije Universiteit Brussel 12
Camel-IDS NV – Key Competitors 13
Camel-IDS NV – Key Employees 14
Camel-IDS NV – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Camel-IDS NV, Pharmaceuticals & Healthcare, Key Facts 2
Camel-IDS NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Camel-IDS NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Camel-IDS NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Camel-IDS NV, Deals By Therapy Area, 2011 to YTD 2017 8
Camel-IDS NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Camel-IDS Raises USD1.5 Million in Seed Financing 10
Camel-IDS Plans to Raise USD7 Million in Series A Financing 11
Camel-IDS Enters into Licensing Agreement with Vrije Universiteit Brussel 12
Camel-IDS NV, Key Competitors 13
Camel-IDS NV, Key Employees 14

★海外企業調査レポート[Camel-IDS NV-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ProQR Therapeutics NV (PRQR):企業の財務・戦略的SWOT分析
    Summary ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders. The company’s lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide …
  • Schindler Holding Ltd.:戦略・SWOT・企業財務分析
    Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report Summary Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Turkiye Halk Bankasi AS:企業の戦略・SWOT・財務分析
    Turkiye Halk Bankasi AS - Strategy, SWOT and Corporate Finance Report Summary Turkiye Halk Bankasi AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Sfinks Polska S.A.
    Sfinks Polska S.A. - Strategy, SWOT and Corporate Finance Report Summary Sfinks Polska S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • ABB Ltd (ABBN)-エネルギー分野:企業M&A・提携分析
    Summary ABB Ltd. (ABB) is a provider of power and automation technologies. The company provides solutions for secure, energy-efficient generation, transmission and distribution of electricity and for increasing productivity in industrial, commercial and utility operations. ABB’s product and service …
  • Taragenyx Ltd:製品パイプライン分析
    Summary Taragenyx Ltd (Taragenyx) is a medical technology company that offers regenerative medicine technology, medical and biological engineering solutions. The company provides restorative implant solutions generation, burdensome operations, and medical, orthopedic and dental implantation solution …
  • Catholic University of Leuven:医療機器:M&Aディール及び事業提携情報
    Summary Catholic University of Leuven (KU Leuven) is a scientific research and educational service provider that provides bachelors degree, post graduate degree and doctorate degree programs. The university provides educational courses in the areas of psychology and educational sciences, arts, law, …
  • Insys Therapeutics Inc (INSY)-製薬・医療分野:企業M&A・提携分析
    Summary Insys Therapeutics Inc (Insys) is a specialty pharmaceutical company, which discovers, develops and commercializes novel drug delivery systems. The company’s flagship product, Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients. Its lead prod …
  • Fiat Chrysler Automobiles NV:戦略・SWOT・企業財務分析
    Fiat Chrysler Automobiles NV - Strategy, SWOT and Corporate Finance Report Summary Fiat Chrysler Automobiles NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Tallink Grupp AS:企業の戦略・SWOT・財務情報
    Tallink Grupp AS - Strategy, SWOT and Corporate Finance Report Summary Tallink Grupp AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Farouk Systems, Inc:企業の戦略・SWOT・財務情報
    Farouk Systems, Inc - Strategy, SWOT and Corporate Finance Report Summary Farouk Systems, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Allergy Therapeutics Plc (AGY)-製薬・医療分野:企業M&A・提携分析
    Summary Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers a wide range of aluminium-free allergy vaccines and diagnostics. It uses Micro Crystalline Tyrosine (MCT) as an alter …
  • Hokuriku Electric Power Co (9505):企業の財務・戦略的SWOT分析
    Hokuriku Electric Power Co (9505) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Go-Ahead Group Plc:企業の戦略・SWOT・財務分析
    Go-Ahead Group Plc - Strategy, SWOT and Corporate Finance Report Summary Go-Ahead Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Esprit Holdings Limited:企業の戦略・SWOT・財務分析
    Esprit Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Esprit Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Nationwide Children’s Hospital-製薬・医療分野:企業M&A・提携分析
    Summary Nationwide Children's Hospital (Nationwide Children's) is a provider of pediatric health care and research services. The hospital offers pediatric services in the areas of gastroenterology, hematology and nutrition, heart care, left lip and palate, oncology ad bone marrow transplantation. It …
  • Murree Brewery Co. Ltd.:企業の戦略・SWOT・財務分析
    Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Agro Tech Foods Limited:企業の戦略・SWOT・財務情報
    Agro Tech Foods Limited - Strategy, SWOT and Corporate Finance Report Summary Agro Tech Foods Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Nurix Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Nurix Inc (Nurix) formerly Kura Therapeutics Inc, is a drug development company that discovers and develops drugs which work by modulating the protein regulation machinery of the cell. The company developed a drug discovery platform based on understanding of the ubiquitin proteasome system ( …
  • Aero Precision Industries, Inc.:企業の戦略・SWOT・財務情報
    Aero Precision Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Aero Precision Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆